Exercise and Time of Day in Type 2 Diabetes
Exercise Time of Day for Cardiometabolic Health in Type 2 Diabetes
1 other identifier
interventional
30
1 country
3
Brief Summary
The overall purpose of the study is to test the effect of Noom on exercise and diet advice in adults with type 2 diabetes. The overarching hypothesis is that the use of Noom may promote better dietary adherence during an exercise program, thereby promoting greater weight loss and cardiometabolic health compared to lifestyle advice only. In particular, the investigators anticipate that changes in metabolic and vascular insulin sensitivity will correlate with glycemic control and blood pressure changes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable diabetes-mellitus-type-2
Started Sep 2021
Longer than P75 for not_applicable diabetes-mellitus-type-2
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 25, 2021
CompletedFirst Submitted
Initial submission to the registry
October 26, 2021
CompletedFirst Posted
Study publicly available on registry
November 5, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2026
CompletedJune 15, 2025
June 1, 2025
4.3 years
October 26, 2021
June 11, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Body Weight
The primary outcome is changes in body weight pre- and post-intervention
Over the course of 2 weeks.
Secondary Outcomes (2)
Glucose Tolerance
Over the course of 2 weeks.
Flow-mediated dilation
Over the course of 2 weeks.
Study Arms (2)
Morning Exercise
EXPERIMENTALIf subjects are randomly assigned to this group, they will participate in exercise training in the morning at a moderate to hard intensity. Subjects will be asked to regularly engage in morning exercise while supervised for about 2 weeks.
Afternoon Exercise
ACTIVE COMPARATORIf subjects are assigned to this group, they will participate in the same exercise program but after in the afternoon.
Interventions
Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the morning.
Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the afternoon.
Eligibility Criteria
You may qualify if:
- Male or female \>30 and \<70 years old.
- Has a body mass index \>28 and \<45 kg/m2.
- Previously diagnosed with T2DM.
- Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).
You may not qualify if:
- Morbidly obese patients (BMI \>46 kg/m2) and overweight/lean patients (BMI \<27 kg/m2)
- Evidence of type 1 diabetes and diabetics requiring insulin therapy
- Subjects who have not been weight stable (\>2 kg weight change in past 3 months)
- Subjects who have been recently active (\>30 min of moderate/high intensity exercise, 2 times/week).
- Subjects who are smokers or who have quit smoking \<1 years ago
- Subjects with abnormal estimated glomerular filtration rate (eGFR).
- Hypertriglyceridemic (\>400 mg/dl) and hypercholesterolemic (\>260 mg/dl) subjects
- Hypertensive (\>160/100 mmHg)
- Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures or impact subject safety.
- Pregnant (as evidenced by positive urine pregnancy test) or nursing women
- Subjects with contraindications to participation in an exercise training program
- Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzphetamine, diethylpropion, phendimetrazine)
- Known hypersensitivity to perflutren (contained in Definity)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rutgers, The State University of New Jerseylead
- Noom Inc.collaborator
Study Sites (3)
New Jersey Institute for Food, Nutrition, and Health
New Brunswick, New Jersey, 08901, United States
Robert Wood Johnson University Hospital Clinical Research Center
New Brunswick, New Jersey, 08901, United States
Rutgers University Loree Gymnasium
New Brunswick, New Jersey, 08901, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Steven K Malin, PhD
Rutgers University - New Brunswick
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
October 26, 2021
First Posted
November 5, 2021
Study Start
September 25, 2021
Primary Completion
December 31, 2025
Study Completion
February 28, 2026
Last Updated
June 15, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share